How to buy CytomX Therapeutics stock

CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 144 staff and has a trailing 12-month revenue of around 0.00.

CytomX Therapeutics share price

Use our graph to track the performance of CTMX stocks over time.

CytomX Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$6.38 - $15.44
50-day moving average	$8.11
200-day moving average	$7.63
Wall St. target price	$13.19
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.20

Buy CytomX Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy CytomX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of CytomX Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CytomX Therapeutics financials

Revenue TTM	$100.4 million
Gross profit TTM	$100.4 million
Return on assets TTM	-8.68%
Return on equity TTM	-65.17%
Profit margin	-32.77%
Book value	$1.03
Market capitalisation	$642 million

TTM: trailing 12 months

Shorting CytomX Therapeutics shares

There are currently 6.2 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 3.6% down from 6.4 million last month.

There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.

CytomX Therapeutics's "short interest ratio" (SIR)

CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 1.0 million). CytomX Therapeutics's SIR currently stands at 5.99. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 5990 shares are currently held short.

However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.0973% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 97 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.

Find out more about how you can short CytomX Therapeutics stock.

CytomX Therapeutics share dividends

We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.

CytomX Therapeutics share price volatility

Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $6.38 up to $15.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6161. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).

CytomX Therapeutics overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, ImmunoGen, Inc.

Frequently asked questions

• What percentage of CytomX Therapeutics is owned by insiders or institutions?

  Currently 2.058% of CytomX Therapeutics shares are held by insiders and 74.561% by institutions.

• How many people work for CytomX Therapeutics?

  Latest data suggests 144 work at CytomX Therapeutics.

• When does the fiscal year end for CytomX Therapeutics?

  CytomX Therapeutics's fiscal year ends in December.

• Where is CytomX Therapeutics based?

  CytomX Therapeutics's address is: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

• What is CytomX Therapeutics's ISIN number?

  CytomX Therapeutics's international securities identification number is: US23284F1057

• What is CytomX Therapeutics's CUSIP number?

  CytomX Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23284F105